O
GILD icon

OrbiMed’s Gilead Sciences GILD Stock Holding History

OrbiMed’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-75,000
Closed -$5.32M – 139
2014
Q1 		$5.32M Buy
+75,000
New +$5.88M 0.07% 115

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

OrbiMed's GILD Position: Q1 2026 in Review

OrbiMed opened a new position in Gilead Sciences (GILD) in Q1 2026: 59,600 shares worth $8.31M. The stake represents 0.16% of the portfolio and ranks #83 among its holdings. This is a return to the name: OrbiMed previously reported a position in GILD as recently as Q1 2025.

OrbiMed first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $401M in Q4 2014. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • OrbiMed held 59,600 shares of Gilead Sciences worth $8.31M as of Q1 2026.
  • Gilead Sciences was a new OrbiMed position in Q1 2026.
  • Gilead Sciences made up 0.16% of OrbiMed's portfolio in Q1 2026, its #83 holding.
  • OrbiMed first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
  • OrbiMed's Gilead Sciences position peaked at $401M in Q4 2014.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.